Mechanisms of Intrinsic Tumor Resistance to Immunotherapy
AbstractAn increased understanding of the interactions between the immune system and tumors has opened the door to immunotherapy for cancer patients. Despite some success with checkpoint inhibitors including ipilimumab, pembrolizumab, and nivolumab, most cancer patients remain unresponsive to such immunotherapy, likely due to intrinsic tumor resistance. The mechanisms most likely involve reducing the quantity and/or quality of antitumor lymphocytes, which ultimately are driven by any number of developments: tumor mutations and adaptations, reduced neoantigen generation or expression, indoleamine 2,3-dioxygenase (IDO) overexpression, loss of phosphatase and tensin homologue (PTEN) expression, and overexpression of the Wnt–β-catenin pathway. Current work in immunotherapy continues to identify various tumor resistance mechanisms; future work is needed to develop adjuvant treatments that target those mechanisms, in order to improve the efficacy of immunotherapy and to expand its scope. View Full-Text
Share & Cite This Article
Rieth, J.; Subramanian, S. Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. Int. J. Mol. Sci. 2018, 19, 1340.
Rieth J, Subramanian S. Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. International Journal of Molecular Sciences. 2018; 19(5):1340.Chicago/Turabian Style
Rieth, John; Subramanian, Subbaya. 2018. "Mechanisms of Intrinsic Tumor Resistance to Immunotherapy." Int. J. Mol. Sci. 19, no. 5: 1340.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.